SGCB and chronic thromboembolic pulmonary hypertension: Disruption of the NO-sGC-cGMP signaling pathway is central to the pathogenesis of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), in which endothelial dysfunction leads to impaired NO synthesis.